Climb Bio (CLYM) Capital Expenditures (2024 - 2026)
Climb Bio's (CLYM) quarterly Capital Expenditures came in at $1.4 million in Q3 2025, up 9686.67% YoY from $14693.5 in Q3 2024, and up 2078.79% on a QoQ basis from $66000.0 in Q2 2025.
Climb Bio (CLYM) Capital Expenditures (2024 - 2026) Analysis & Trends
Climb Bio (CLYM) has 2 years of Capital Expenditures data on file, last reported at $1.4 million in Q3 2025.
- Quarterly Capital Expenditures rose 9686.67% year-over-year to $1.4 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 616.19% YoY) and the FY2025 annual result came in at $1.5 million, up 657.0% from the prior year.
- Capital Expenditures rose to $1.4 million in Q3 2025, from $66000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q3 2025 to a low of -$15000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -304,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304,000.00 |
| Jun 30, 2026 | -304,000.00 |
| Sep 30, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Sep 30, 2024 | -15,000.00 |